ABOUT US

ABOUT US

The ultimate solution for aortic diseases

The ultimate solution for aortic diseases

Aortyx is a pioneer company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona that aims at providing a new generation of endovascular devices to treat vascular diseases. Our technology focuses on tissue regeneration by mimicking the aorta biomechanical environment. It provides a suitable milieu for cell migration and proliferation in a bioresorbable platform that minimizes differences with the natural dynamics of the aorta.

At Aortyx, we aim at delivering the ultimate solution for aortic diseases, tackling clear unmet needs, generating positive impact in our society with the most advanced available technology.

Aortyx is a pioneer company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona that aims at providing a new generation of endovascular devices to treat vascular diseases. Our technology focuses on tissue regeneration by mimicking the aorta biomechanical environment. It provides a suitable milieu for cell migration and proliferation in a bioresorbable platform that minimizes differences with the natural dynamics of the aorta.

At Aortyx, we aim at delivering the ultimate solution for aortic diseases, tackling clear unmet needs, generating positive impact in our society with the most advanced available technology.

To date, we have been supported by FIPSE (2016 and 2018), the Catalan government through Llavor (2016) and Producte (2018), Fundació “la Caixa” through CaixaImpulse (2017). Most recently, we have received funding from EIT Health through Headstart (2019), Neotec CDTI (2019), Pyme Innovadora, Retos Colaboración 2019, the European Union’s Horizon 2020 research and innovation program under grant agreement H2020-SMEINST-876061_AORTYX.

To date, we have been supported by FIPSE (2016 and 2018), the Catalan government through Llavor (2016) and Producte (2018), Fundació “la Caixa” through CaixaImpulse (2017). Most recently, we have received funding from EIT Health through Headstart (2019), Neotec CDTI (2019), Pyme Innovadora, Retos Colaboración 2019, the European Union’s Horizon 2020 research and innovation program under grant agreement H2020-SMEINST-876061_AORTYX.